UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018369
Receipt number R000021128
Scientific Title Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD).
Date of disclosure of the study information 2015/08/01
Last modified on 2018/12/14 15:37:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD).

Acronym

The exploratory study of Yokukansankachimpihange on BPSD in patients with AD.

Scientific Title

Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD).

Scientific Title:Acronym

The exploratory study of Yokukansankachimpihange on BPSD in patients with AD.

Region

Japan


Condition

Condition

AD patients with BPSD

Classification by specialty

Neurology Psychiatry Neurosurgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate exploratively the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of Alzheimer's disease in a single-armed, open-label study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in neuropsychiatric inventory (NPI) total score before and after Yokukansankachimpihange treatment

Key secondary outcomes

Changes in neuropsychiatric inventory (NPI) subscale score before and after Yokukansankachimpihange treatment


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Yokukansankachimpihange treatment for 12 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit

89 years-old >=

Gender

Male and Female

Key inclusion criteria

1) probable AD
2) Within normal limit of serum potassium.
3) Have a study partner able to provide an independent evaluation of functioning.
4) Agreement to sign an informed consent.

Key exclusion criteria

1) Patients with neurological disease to affect the cognitive function except AD.
2) Patients who have local lesion which affected the cognitive function by CT or MRI.
3) Patients with serious diseases such as malignant tumors, or disorder which is not in stable condition.
4) Patient who has an allergy to Kampo medicine.
5) Patients considered inappropriate by the study investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaru Mimura

Organization

Keio University School of Medicine

Division name

Department of Neuropsychiatry

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo 160_8582, Japan

TEL

03-5363-3828

Email

mimura@a7.keio.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryutaro Arita

Organization

Keio University School of Medicine

Division name

Center for Kampo Medicine

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo 160_8582, Japan

TEL

03-5366-3824

Homepage URL

http://www.keio-kampo.jp/ja_2/page07.html

Email

tarikun@a6.keio.jp


Sponsor or person

Institute

Keio University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

TSUMURA & CO.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

慶應義塾大学医学部(東京都)


Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.scirp.org/Journal/PaperInformation.aspx?PaperID=89050

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 07 Month 10 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 01 Day

Last follow-up date

2017 Year 03 Month 31 Day

Date of closure to data entry

2017 Year 04 Month 01 Day

Date trial data considered complete

2017 Year 04 Month 10 Day

Date analysis concluded

2017 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 07 Month 21 Day

Last modified on

2018 Year 12 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021128


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name